Portal Pre-Commitment Prompt, Tailored R/R Messages w/ Direct Scheduling + Pre-Appointment Reminders for Respiratory Tract Infections

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of California, Los Angeles, Los Angeles, CA
Respiratory Tract Infections+2 More
Text Fixed R/R Messages with Direct Appointment Schedule Link - Behavioral
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. The study design is a 2x2 nested factorial design. Patients will be randomized into 1) receiving text based reminder messages with direct scheduling link, 2) portal-based reminder messages with direct scheduling link, or 3) the control group. Patients randomized to the intervention arms will receive reminders if they are due for influenza vaccine. Nested within the portal reminder arm, we will have two additional components for which patients will be randomized separately: A pre-commitment prompt, asking patients which time (September, October, November or December) and which place (UCLA, pharmacy, workplace or school, or other) they plan to get their Influenza vaccine with tailored monthly messages based on responses (pre-commitment message with tailored recall messages with direct scheduling vs. standard portal reminders with direct scheduling). A pre-appointment reminder encouraging patients to ask for their influenza vaccine at their upcoming appointment (pre-appointment reminder encouraging influenza vaccination vs. standard pre-appointment reminder not mentioning influenza vaccination) Nested within the text message reminder arm, we will have one additional component for which patients will be randomized separately: 1) A pre-appointment reminder encouraging patients to ask for their influenza vaccine at their upcoming appointment (pre-appointment reminder encouraging influenza vaccination vs. standard pre-appointment reminder not mentioning influenza vaccination) Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive an annual flu vaccine, vaccination rates remain low: at 6m-4.9 yrs. (70%), 5-17.9 yrs. (56%), 18-64.9 yrs. (38%), and >65 yrs. (63%). The investigators will assess the effectiveness of MyChart R/R messages and text R/R messages as compared to the standard of care control (no messages).

Eligible Conditions

  • Flu caused by Influenza
  • Respiratory Tract Infections

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Receipt of the Annual Influenza Vaccine Among Adult Index Patients
Receipt of the Annual Influenza Vaccine Among Pediatric Index Patients

Trial Safety

Trial Design

7 Treatment Groups

Portal Pre-Commitment Prompt, Tailored R/R Messages w/ Direct Scheduling + Pre-A...
1 of 7
Portal Fixed R/R Messages with Direct Appointment Schedule Link
1 of 7
Text Fixed R/R Messages with Direct Appointment Schedule Link
1 of 7
Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment ...
1 of 7
Portal Fixed R/R Messages with Direct Appointment Schedule Link + Portal Pre-App...
1 of 7
Text Fixed R/R Messages with Direct Appointment Schedule Link + Text Pre-Appoint...
1 of 7
No R/R Message or Pre-Appointment Reminder
1 of 7
Active Control

240000 Total Participants · 7 Treatment Groups

Primary Treatment: Portal Pre-Commitment Prompt, Tailored R/R Messages w/ Direct Scheduling + Pre-Appointment Reminders · No Placebo Group · N/A

Portal Pre-Commitment Prompt, Tailored R/R Messages w/ Direct Scheduling + Pre-Appointment RemindersActiveComparator Group · 2 Interventions: Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link, Portal Pre-Appointment Reminder · Intervention Types: Behavioral, Behavioral
Portal Fixed R/R Messages with Direct Appointment Schedule Link
Behavioral
ActiveComparator Group · 1 Intervention: Portal Fixed R/R Messages with Direct Appointment Schedule Link · Intervention Types: Behavioral
Text Fixed R/R Messages with Direct Appointment Schedule Link
Behavioral
ActiveComparator Group · 1 Intervention: Text Fixed R/R Messages with Direct Appointment Schedule Link · Intervention Types: Behavioral
Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link
Behavioral
ActiveComparator Group · 1 Intervention: Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link · Intervention Types: Behavioral
Portal Fixed R/R Messages with Direct Appointment Schedule Link + Portal Pre-Appointment ReminderActiveComparator Group · 2 Interventions: Portal Fixed R/R Messages with Direct Appointment Schedule Link, Portal Pre-Appointment Reminder · Intervention Types: Behavioral, Behavioral
Text Fixed R/R Messages with Direct Appointment Schedule Link + Text Pre-Appointment RemindersActiveComparator Group · 2 Interventions: Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder · Intervention Types: Behavioral, Behavioral
No R/R Message or Pre-Appointment ReminderNoIntervention Group · 1 Intervention: No R/R Message or Pre-Appointment Reminder · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Trial Background

Peter G Szilagyi, MD
Principal Investigator
University of California, Los Angeles
Closest Location: University of California, Los Angeles · Los Angeles, CA
Photo of Los Angeles  1Photo of Los Angeles  2Photo of Los Angeles  3
2004First Recorded Clinical Trial
6 TrialsResearching Respiratory Tract Infections
216 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.